1
Sierra David H, Luck Edward E, Brown Dennis M: Surgical adhesive material.. Project Hear, Matrix Pharma, November 8, 1989: EP0341007-A2 (42 worldwide citation)

The present invention provides a surgical adhesive comprising, in an aqueous composition, patient autogenous plasma, collagen, thrombin, and optionally, an antifibrinolytic agent. The present adhesive is formed from the patient's plasma without the use of any added reagents for concentration or isol ...


2
Sierra David H, Luck Edward E, Brown Dennis M: Fibrin/collagen membrane material for biomedical use.. Matrix Pharma, May 13, 1992: EP0485210-A2 (29 worldwide citation)

Gel membranes are provided by gelling fibrinogen with thrombin by itself or in combination with gelation of collagen. After dehydration, the resulting membranes may be used as dressings, temporary skin grafts, or the like. The gels may be used without dehydration for drug delivery or tissue regenera ...


3
Brown Dennis M: Formulations and methods of administration of cephalotaxines, including homoharringtonine. Chemgenex Pharmaceuticals, Brown Dennis M, TRECARTIN Richard F, January 29, 2004: WO/2004/009092 (11 worldwide citation)

The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment ...


4
Luck Edward E, Brown Dennis M: Compostions for treating intracranial tumors.. Matrix Pharma, August 16, 1989: EP0328389-A2 (4 worldwide citation)

Intracranial abnormal solid cellular masses, particularly tumors or adjacent tissues that may contain tumor cells, are treated by administering to the abnormal area a sufficient amount of a cytotoxic drug comprising a vinca alkaloid dispersed in a stable flowable proteinaceous matrix. The matrix sub ...


5

6
Brown Dennis M: Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof. Chemgenex Pharmaceuticals, Brown Dennis M, TRECARTIN Richard F, January 29, 2004: WO/2004/009030 (2 worldwide citation)

The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inh ...


7
BROWN DENNIS M: Method of making ceramic bodies having reduced shape variability. BROWN DENNIS M, Santandrea Robert P, March 3, 2011: WO/2011/026065 (1 worldwide citation)

A method of making ceramic bodies having reduced shape variability. Such ceramic bodies include extruded-to-shape substrates and diesel particulate filters. Principal components analysis is used to generate a small number of uncorrelated or independent components from a larger set of inter-correlate ...


8
BROWN Dennis M: Procédé de synthèse dhexitols substitués comme le dianhydrogalactitol, Method of synthesis of substituted hexitols such as dianhydrogalactitol. Del Mar Pharmaceuticals, BROWN Dennis M, FARBER Michael B, February 23, 2012: WO/2012/024368 (1 worldwide citation)

The present invention provides an efficient method of synthesizing and purifying dianhydrohexitols such as dianhydrogalactitol. In general, as applied to dianhydrogalactitol, the method comprises: (1) reacting dulcitol with a concentrated solution of hydrobromic acid at a temperature of about 80° C ...


9
Brown Dennis M: Naphthalimide dosing by n-acetyl transferase genotyping. Chemgenex Pharmaceuticals, October 18, 2006: EP1711634-A2

The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combin ...


10
Brown Dennis M: Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof. Chemgenex Pharmaceuticals, June 15, 2005: EP1539179-A2

The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inh ...